Leukemia treatment study for children with AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a treatment plan for children under 18 with a new diagnosis of acute myeloid leukemia (AML). It aims to provide effective therapy based on standard guidelines, and may include children with certain blood or bone marrow findings even if tests are limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be under 18 years old when starting the study
- Must have a new diagnosis of acute myeloid leukemia (AML) according to the latest classification
- Must have at least 20% leukemia cells in the bone marrow, or a high number in the blood if bone marrow testing is unsafe
- Must not have certain other types of leukemia (like promyelocytic leukemia or mixed phenotype leukemia)
- Must not be pregnant, have Down syndrome (trisomy 21), or have had other cancer treatments before (except hydroxyurea, steroids, or chemotherapy given into the spinal fluid)
- Must be able to start treatment as outlined in the hospital's AML therapy plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This trial tests an experimental treatment called BG1805 for children with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. BG1805 is a type of cell therapy (like CAR-T) that targets the CLL-1 marker on leukemia cells, potentially helping the body fight the cancer.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This study looks at how adults with acute myeloid leukemia (AML) are treated and how they fare over time. The goal is to better understand the disease and improve care.
This trial aims to help doctors choose the best treatment for older adults with acute myeloid leukemia (AML) by using a special health assessment that looks at your overall well-being. The study will compare different treatment options based on this assessment, with the goal of improving outcomes and quality of life.
Hear when a new Acute Myeloid Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.